8-K: INOVIO Reports Progress on BLA Submission for INO-3107 and Announces 2024 Financial Results

INOVIO reports significant progress towards submitting a BLA for INO-3107, resolves manufacturing issues, and announces its financial results for the fourth quarter and full year 2024.

Summary

• INOVIO is making strides toward submitting a Biologics License Application (BLA) for INO-3107 for recurrent respiratory papillomatosis (RRP).
• The company resolved a manufacturing issue related to the CELLECTRA device, a key component for delivering INO-3107.
• INOVIO plans to begin a rolling submission of the BLA in mid-2025 and aims for FDA acceptance by the end of the year.
• Retrospective study data showed 50% of patients achieved a Complete Response in the second year of treatment with INO-3107, and 86% experienced a reduction in surgery.
• Interim results from a Phase 1 trial of DNA-encoded monoclonal antibodies (DMAb) targeting COVID-19 showed the technology was well-tolerated and produced long-lasting in vivo antibody production.
• INOVIO's cash, cash equivalents, and short-term investments totaled $94.1 million as of December 31, 2024, compared to $145.3 million the previous year.
• Total revenues for 2024 were $218,000, down from $832,000 in 2023.
• Research and Development (R&D) expenses decreased to $75.6 million in 2024 from $86.7 million in 2023.
• General and Administrative (G&A) expenses also decreased to $37.0 million from $47.6 million in the same period.
• The net loss for 2024 was $107.3 million, or $3.95 per share, compared to a net loss of $135.1 million, or $6.09 per share, in 2023.
• INOVIO estimates its current cash balance will support operations into the first quarter of 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress on its key program, INO-3107, and has resolved a significant manufacturing issue. However, the financial results show a decrease in revenue and a net loss, which tempers the overall positive outlook.

Positives

• The company is on track to submit its first BLA for INO-3107, marking a potential transition to a commercial-stage company.
• The resolution of the CELLECTRA device manufacturing issue removes a significant hurdle for BLA submission.
• Retrospective trial data for INO-3107 shows durable clinical benefit for RRP patients.
• DMAb technology demonstrates potential for long-term therapeutic antibody production without anti-drug antibodies.
• The company has sufficient cash to fund operations into the first quarter of 2026.
• The European Medicines Agency's Committee for Advanced Therapies (CAT) certified the quality and non-clinical data for INO-3107.
• INO-3107 was designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP).

Negatives

• Total revenues decreased significantly in 2024 compared to 2023, from $832,000 to $218,000.
• The company experienced a net loss of $107.3 million in 2024.
• Cash reserves decreased from $145.3 million at the end of 2023 to $94.1 million at the end of 2024.

Risks

• The BLA submission for INO-3107 is subject to FDA review and approval, which is not guaranteed.
• Clinical trials and product development programs are subject to inherent uncertainties.
• The company's cash runway is projected to last into the first quarter of 2026, but this projection does not include any further capital-raising activities.
• The company's success depends on the ability of its collaborators to attain development and commercial milestones.
• The company faces competition from alternative therapies or treatments for the conditions targeted by its products.

Future Outlook

INOVIO anticipates starting the rolling submission of its BLA for INO-3107 in mid-2025, with the goal of FDA acceptance by the end of the year, and expects its current cash balance to support operations into the first quarter of 2026.

Management Comments

• Dr. Jacqueline Shea, INOVIO's President and CEO, stated that INOVIO's recent progress puts them on the cusp of achieving several long-term goals for their DNA medicines, most importantly the submission of their first BLA and potential transition to a commercial-stage company.
• Dr. Michael Sumner, INOVIO's Chief Medical Officer, said that they are extremely pleased with recently announced data from a proof-of-concept trial with their DMAb technology that showed durable in vivo antibody production.

Industry Context

INOVIO's focus on DNA medicines and its proprietary CELLECTRA delivery system positions it within the competitive landscape of gene therapies and vaccine development. The progress with INO-3107 and the DMAb technology could provide a competitive edge in treating HPV-related diseases and infectious diseases, respectively.

Comparison to Industry Standards

• The reported 50% complete response rate in RRP patients treated with INO-3107 in the retrospective trial is a notable outcome, potentially comparing favorably to existing treatment options for RRP, which often involve repeated surgeries.
• The DMAb technology's ability to achieve durable in vivo antibody production without generating anti-drug antibodies could be a significant advantage compared to other gene-based delivery platforms like adeno-associated virus (AAV) vectors, which can elicit immune responses.
• The company's cash runway into Q1 2026 provides a degree of financial stability, but it's shorter than some other biotech companies at a similar stage of development, potentially requiring further capital raises.

Management Changes

Stakeholder Impact

• Shareholders: The progress on INO-3107 and DMAb technology could positively impact shareholder value, while the financial results and potential need for further capital raises could have a negative impact.
• Employees: The company's progress and financial stability impact job security and potential for growth.
• Patients: The development of INO-3107 and other DNA medicines could provide new treatment options for HPV-related diseases, cancer, and infectious diseases.
• Collaborators: The company's ability to achieve milestones and secure funding impacts the success of collaborative projects.

Next Steps

• Complete FDA-required design-verification testing for CELLECTRA device.
• Update IND and initiate confirmatory trial for INO-3107.
• Submit BLA to the FDA, beginning with a rolling submission process in mid-2025.
• Submit a long-term study protocol to the FDA following BLA submission.
• Present and publish clinical, immunology, and durability data at scientific and medical conferences in 2025.
• Finalize protocol of the Phase 3 trial for INO-3112 in consultation with the FDA.
• Complete ongoing manufacture of drug supply for the Phase 3 trial for INO-3112.
• Finalize trial protocols and seek funding to support trial activities for INO-4201.
• Complete manufacture of drug supply for the next trial of INO-5401.

Key Dates